289 related articles for article (PubMed ID: 37451822)
21. MUC1 glycopeptide epitopes predicted by computational glycomics.
Song W; Delyria ES; Chen J; Huang W; Lee JS; Mittendorf EA; Ibrahim N; Radvanyi LG; Li Y; Lu H; Xu H; Shi Y; Wang LX; Ross JA; Rodrigues SP; Almeida IC; Yang X; Qu J; Schocker NS; Michael K; Zhou D
Int J Oncol; 2012 Dec; 41(6):1977-84. PubMed ID: 23023583
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
23. Synthetic vaccines from tumor-associated glycopeptide antigens.
Westerlind U; Kunz H
Chimia (Aarau); 2011; 65(1-2):30-4. PubMed ID: 21469441
[TBL] [Abstract][Full Text] [Related]
24. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
25. [Covalent organic framework functional materials and their applications in glycopeptide enrichment].
Sheng Q; Zhou Y; Zhao Z; Wang Y; Li W; Ke Y; Lan M; Qing G; Liang X
Se Pu; 2021 Jun; 39(6):588-598. PubMed ID: 34227319
[TBL] [Abstract][Full Text] [Related]
26. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
Stepensky D; Tzehoval E; Vadai E; Eisenbach L
Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
[TBL] [Abstract][Full Text] [Related]
27. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.
Ryan SO; Vlad AM; Islam K; Gariépy J; Finn OJ
Biol Chem; 2009 Jul; 390(7):611-8. PubMed ID: 19426130
[TBL] [Abstract][Full Text] [Related]
28. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.
Verel I; Heider KH; Siegmund M; Ostermann E; Patzelt E; Sproll M; Snow GB; Adolf GR; van Dongen GA
Int J Cancer; 2002 May; 99(3):396-402. PubMed ID: 11992408
[TBL] [Abstract][Full Text] [Related]
29. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
30. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity.
Galli-Stampino L; Meinjohanns E; Frische K; Meldal M; Jensen T; Werdelin O; Mouritsen S
Cancer Res; 1997 Aug; 57(15):3214-22. PubMed ID: 9242452
[TBL] [Abstract][Full Text] [Related]
31. Antibody recognition of a unique tumor-specific glycopeptide antigen.
Brooks CL; Schietinger A; Borisova SN; Kufer P; Okon M; Hirama T; Mackenzie CR; Wang LX; Schreiber H; Evans SV
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10056-61. PubMed ID: 20479270
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.
Koh XY; Koh XH; Hwang LA; Ferrer FJ; Rahmat SAB; Lama D; Lane DP
Oncogene; 2019 Nov; 38(48):7342-7356. PubMed ID: 31417186
[TBL] [Abstract][Full Text] [Related]
33. CD44v6-targeted CAR T-cells specifically eliminate CD44 isoform 6 expressing head/neck squamous cell carcinoma cells.
Haist C; Schulte E; Bartels N; Bister A; Poschinski Z; Ibach TC; Geipel K; Wiek C; Wagenmann M; Monzel C; Scheckenbach K; Hanenberg H
Oral Oncol; 2021 May; 116():105259. PubMed ID: 33895463
[TBL] [Abstract][Full Text] [Related]
34. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
35. Role of glycosylation on the ensemble of conformations in the MUC1 immunodominant epitope.
Singh J; Her C; Supekar N; Boons GJ; Krishnan VV; Brooks CL
J Pept Sci; 2020 Jan; 26(1):e3229. PubMed ID: 31729101
[TBL] [Abstract][Full Text] [Related]
36. Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation.
McComb S; Nguyen T; Shepherd A; Henry KA; Bloemberg D; Marcil A; Maclean S; Zafer A; Gilbert R; Gadoury C; Pon RA; Sulea T; Zhu Q; Weeratna RD
Front Immunol; 2022; 13():864868. PubMed ID: 35935988
[TBL] [Abstract][Full Text] [Related]
37. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
38. A novel monoclonal antibody to a defined peptide epitope in MUC16.
Marcos-Silva L; Ricardo S; Chen K; Blixt O; Arigi E; Pereira D; Høgdall E; Mandel U; Bennett EP; Vakhrushev SY; David L; Clausen H
Glycobiology; 2015 Nov; 25(11):1172-82. PubMed ID: 26201951
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of glycosylation of herpes simplex virus glycoproteins: identification of antigenic and immunogenic partially glycosylated glycopeptides on the cell surface membrane.
Glorioso J; Szczesiul MS; Marlin SD; Levine M
Virology; 1983 Apr; 126(1):1-18. PubMed ID: 6189286
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
